Wednesday, November 10, 2010 10:12:16 PM
Recent CHRS News
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:51:06 PM
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/21/2024 09:14:58 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 08:35:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:51:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:17:04 PM
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:30:11 AM
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 05/08/2024 01:00:00 PM
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 02:02:18 PM
- Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting • GlobeNewswire Inc. • 04/08/2024 12:30:00 PM
- Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update • GlobeNewswire Inc. • 03/13/2024 08:01:00 PM
- Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 • GlobeNewswire Inc. • 03/05/2024 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 11:22:53 AM
- Coherus Completes Divestiture of Ophthalmology Franchise • GlobeNewswire Inc. • 03/04/2024 06:00:00 AM
- Coherus BioSciences Announces New Employment Inducement Grants • GlobeNewswire Inc. • 02/23/2024 10:33:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:02:44 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 10:00:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:59:29 PM
- Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv • GlobeNewswire Inc. • 02/21/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:09:45 PM
- Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP • GlobeNewswire Inc. • 02/05/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 01:05:42 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM